Erasca Inc (ERAS)

Currency in USD
10.650
+1.540(+16.90%)
Closed·
10.620-0.030(-0.28%)
·
Earnings results expected in 6 days
ERAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.90010.700
52 wk Range
1.06024.280
Key Statistics
Prev. Close
10.65
Open
9.14
Day's Range
8.9-10.7
52 wk Range
1.06-24.28
Volume
12.71M
Average Vol. (3m)
6.57M
1-Year Change
523.9726%
Book Value / Share
1.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ERAS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.700
Upside
+94.37%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Erasca Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

Analyst Ratings

8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 20.700
(+94.37% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy20.00+87.79%-MaintainApr 28, 2026
BofA Securities
Sell9.00-15.49%2.00MaintainApr 28, 2026
Stifel
Buy30.00+181.69%20.00MaintainApr 27, 2026
Mizuho
Buy28.00+162.91%19.00MaintainApr 27, 2026
Jefferies
Buy21.00+97.18%-MaintainApr 20, 2026

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
-0.10 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ERAS Income Statement

Compare ERAS to Peers and Sector

Metrics to compare
ERAS
Peers
Sector
Relationship
P/E Ratio
−26.6x−3.7x−0.5x
PEG Ratio
−0.73−0.090.00
Price / Book
10.2x3.5x2.6x
Price / LTM Sales
-84.5x3.2x
Upside (Analyst Target)
92.5%101.6%48.8%
Fair Value Upside
Unlock−0.5%6.9%Unlock

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
54.86M17.65%499.78M
Other Institutional Investors
204.41M65.77%1.86B
Public Companies & Retail Investors
51.52M16.58%469.39M
Total
310.8M100.00%2.83B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Frazier Life Sciences Management, LP7.31%22,729,436242,068
VR Management, LLC5.75%17,857,083190,178

People Also Watch

79.220
AXTI
+11.47%
164.360
AAOI
+7.54%
902.32
LITE
+5.13%
7.12
POET
+7.88%

FAQ

What Is the Erasca (ERAS) Stock Price Today?

The Erasca stock price today is 10.650 USD.

What Stock Exchange Does Erasca Trade On?

Erasca is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Erasca?

The stock symbol for Erasca is "ERAS."

What Is the Erasca Market Cap?

As of today, Erasca market cap is 3.310B USD.

What Is Erasca's Earnings Per Share (TTM)?

The Erasca EPS (TTM) is -0.439.

When Is the Next Erasca Earnings Date?

Erasca will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is ERAS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Erasca Stock Split?

Erasca has split 0 times.

How Many Employees Does Erasca Have?

Erasca has 103 employees.

What is the current trading status of Erasca (ERAS)?

As of May 01, 2026, Erasca (ERAS) is trading at a price of 10.650 USD, with a previous close of 10.650 USD. The stock has fluctuated within a day range of 8.900 USD to 10.700 USD, while its 52-week range spans from 1.060 USD to 24.280 USD.

What Is Erasca (ERAS) Price Target According to Analysts?

The average 12-month price target for Erasca is 20.700 USD, with a high estimate of 30 USD and a low estimate of 9 USD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +94.37% Upside potential.

What Is the ERAS Premarket Price?

ERAS's last pre-market stock price is 10.620 USD. The pre-market share volume is 13,550.000, and the stock has decreased by -0.030, or -0.280%.

What Is the ERAS After Hours Price?

ERAS's last after hours stock price is 10.680 USD, the stock has decreased by 0.030, or 0.280%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.